secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001193125-25-055602
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03
LLM model:  deepseek-v4-flash:cloud@v2

KalVista changes fiscal year-end from April 30 to December 31
-------------------------------------------------------------

- Board approved change effective March 13, 2025; new fiscal year begins January 1, 2026.
- Transition report on Form 10-KT will cover eight-month period May 1 through Dec 31, 2025.
- During transition, a 10-Q for quarter ending July 31, 2025 will be filed, then quarters shift to Sept 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/0001193125-25-055602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525055602/d938905d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-055602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer